ESR1 and breast carcinoma: Gaur et al. synthesized a series of novel indole-based arylsulfonylhydrazides and evaluated their anticancer activity against estrogen receptor-positive (MCF-7) and triple-negative (MDA-MB-468) breast cancer cell lines [125].